We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Whole-Exome Sequencing Identifies Mitochondrial Disorder Biomarkers

By LabMedica International staff writers
Posted on 13 Jul 2014
Print article
Authors of a recent paper suggested using whole-exome sequencing to identify biomarkers for difficult to diagnose respiratory chain complex defects and other mitochondrial disorders.

In whole-exome sequencing only the portion of the genome (about 1%) that actually encodes for proteins is mapped. This technique is considerably faster and more economical than classical whole-genome sequencing.

Mitochondrial disorders are recognized as a common cause of inherited disease, but their diagnosis remains challenging. Multiple respiratory chain complex defects are particularly difficult to diagnose at the molecular level because of the huge number of nuclear genes potentially involved in mitochondrial protein synthesis, with many not yet linked to human disease.

Investigators at Newcastle University (United Kingdom) sought biomarkers that would be useful for diagnosing respiratory chain complex defects. To this end they used whole-exome sequencing to evaluate 53 patients referred to two national centers in the United Kingdom and Germany between 2005 and 2012. The majority (96%) of the patients developed disease symptoms during childhood (less than 15 years old) and most (66%) developed symptoms within the first year of life. The most frequent clinical features were muscle weakness, central neurological disease, cardiomyopathy, and abnormal liver function; a combination of these abnormalities was present in most cases.

Presumptive causal variants were identified in 28 patients and possible causal variants were identified in four patients. Together these accounted for 32 patients and involved 18 different genes. These included recurrent mutations in the RMND1, AARS2, and MTO1 genes and potential novel mutations in four possible mitochondrial disease genes (VARS2, GARS, FLAD1, and PTCD1). Distinguishing clinical features included deafness and renal involvement associated with RMND1 and cardiomyopathy with AARS2 and MTO1. In 20 patients with prominent heart disease, the causative mutation was detected in 80%, while the detection rate was much lower in patients with liver disease (33%). It was not possible to confidently identify the underlying genetic basis in 21 patients (40%).

The authors concluded that, “Our findings contrast with large-scale candidate gene analysis using conventional and next-generation sequencing approaches, both of which had a lower diagnostic yield (10%–13%) and by definition did not discover new potential disease genes. Additional study is required to determine the utility of this approach compared with traditional diagnostic methods in independent patient populations.”

The study was published in the July 2, 2014, issue of the Journal of the American Medical Association (JAMA).

Related Links:

Newcastle University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.